1	Full Title: Inflammatory cytokines and a diverse cervicovaginal microbiome are associated with
2	cervical disease in Hispanics living in Puerto Rico
3	Short Title: bacterial diversity and cervical cancer in Puerto Rico
4	Eduardo Tosado-Rodríguez <sup>1</sup> , Loyda B. Mendez <sup>2</sup> , Ana M. Espino <sup>1</sup> , Stephanie Dorta-Estremera <sup>1,3</sup> ,
5	Edna E. Aquino <sup>1</sup> , Josefina Romaguera <sup>4</sup> and Filipa Godoy-Vitorino <sup>1*</sup>
6	
7	<sup>1</sup> Department of Microbiology and Medical Zoology, School of Medicine, Medical Sciences
8	Campus, University of Puerto Rico, USA
9	<sup>2</sup> University Ana G. Méndez, Carolina Campus, Carolina, Puerto Rico, USA
10	<sup>3</sup> Cancer Biology, Comprehensive Cancer Center University of Puerto Rico, USA
11	<sup>4</sup> Department of OBGYN, School of Medicine, Medical Sciences Campus, University of Puerto
12	Rico, USA
13	
14	* Corresponding author
15	Filipa Godoy-Vitorino, Ph.D.
16	filipa.godoy@upr.edu
17	
18	Keywords: Cervicovaginal microbiota, Cytokines, 16S rRNA, Hispanics, inflammation
19	
20	

#### 21 Abstract

22 Cervical cancer (CC) is women's fourth most common cancer worldwide. A worrying increase in 23 CC rates in Hispanics suggests that besides Human Papillomaviruses infections, there may be other 24 biological causes promoting the disease. We hypothesized that the cervical microbiome and the 25 epithelial microenvironment favoring inflammation is conducive to disease progression. There is a lack of studies examining the part played by microbial populations in the development of 26 27 precancerous lesions into cancer in Hispanic women. We aimed to investigate the relationship 28 between the cervicovaginal microbiome and inflammation in Hispanic women living in PR while 29 considering cervical neoplasia and HPV infection. Cervical samples collected from 91 participants 30 coming to clinics in San Juan, underwent 16S rRNA genes (V4 region) profiling, and cytokines 31 were measured using Luminex MAGPIX technology. Cytokines were grouped as inflammatory 32 (IL-1β, TNFα, IFNy, IL-6), anti-inflammatory (IL-4, IL-10, TGFβ1), and traffic-associated (IL-33 8, MIP1a, MCP1, IP10). They were related to microbes via an inflammation scoring index based on the quartile and tercile distribution of the cytokine's concentration. We found significant 34 35 differences in the diversity and composition of the microbiota according to HPV risk, cervical 36 disease, and cytokine abundance. The most dominant community state type (CST) was CST IV 37 with ~ 90% dominance in participants with high-grade squamous intraepithelial lesions and high-38 risk HPV. The increasing concentration of pro-inflammatory cytokines was associated with a decrease in L. crispatus. In contrast, dysbiosis-associated bacteria such as Gardnerella, Prevotella, 39 40 Atopobium concomitantly increased with pro-inflammatory cytokines. Our study highlights that the cervical microbiota of Hispanics living in PR is characteristically diverse, regardless of HPV 41 42 status and that dysbiosis associated with a decrease in Lactobacillus marks inflammatory

processes. Therefore, the joint host-microbe interaction analyses via cytokine signaling and
microbiota in precancerous lesions is confirmed to have great translational potential.

45

#### 46 Introduction

47 Cervical cancer (CC) is the 4th most common cancer among women and the 4th leading cause of 48 cancer death in females worldwide (Cohen et al. 2019). Although CC rates have decreased in the 49 USA (Chatterjee et al. 2016), the incidence and mortality from cervical cancer mainly occurs in low resource settings (~ >85%) (Ferlay et al. 2010). According to the Pan American Health 50 51 Organization for 2012, 80% of American deaths due to CC occur in Latin America and the 52 Caribbean (1). Puerto Rico (PR) has the highest age-adjusted incidence of CC in the US (Ortiz et 53 al. 2010), with notably higher incidence from 2001 to 2017, increasing from 9.2 to 13 per 100,000 54 person-years (Ortiz et al. 2021). PR also has a 79.3% CC screening rate that does not achieve 55 CDC's screening recommendations of 93% (Centers for Disease and Prevention 2012; Ortiz et al. 56 2010) posing a strain on health systems in the island (2).

57 Persistent infection with oncogenic Human Papillomavirus (HPV) is the most important cause of 58 CC. HPV infections range from 90–100% prevalence in cervical abnormalities, from high-grade 59 squamous intraepithelial lesion -HGSIL- to severe dysplasia and cancer (3), where the viral 60 genome integration modulates the host cell cycle promoting neoplasia progression (4,5). However, 61 other factors influence cervical disease progression, including lifestyle, genetic predisposition, 62 immunosuppression, early onset of sexual activities, and many pregnancies and deliveries (6-8). 63 Nevertheless, why only a fraction of women acquires a long-lasting, persistent high-risk HPV (HR-64 HPV) that puts them at risk for developing Cervical Intraepithelial Neoplasia (CIN) remains

unknown. One potential explanation for this variation could be the cervicovaginal microbiota and
its related processes. Recent studies suggest an association between certain bacterial community
types of the vaginal microbiota, HPV infection, and cervical disease (9–11). Additionally,
processes like bacterial vaginosis, cervical inflammation, and increased vaginal pH are all known
to affect susceptibility to cervical HPV (12).

70 Women of different ethnic groups differ in their vaginal microbiome signatures (13). The 71 cervicovaginal microbiome has been characterized into five different community state types (CST) 72 according to the dominance of Lactobacillus species, a concept that was introduced in 2011 by 73 Ravel et al. to categorize vaginal microbial communities among reproductive-age women (13). 74 CST-I refers to communities dominated by L. crispatus (CST-I), CST-II by L. gasseri, CST-III 75 by L. iners, CST-V by L. jensenii (CST-V), or non-Lactobacillus dominated and highly diverse 76 profiles such as CST-IV. Furthermore, CST-IV is often characterized by three sub-CSTs: 1) CST 77 IV-A has a high relative abundance of Candidatus *Lachnocurva vaginae* and a moderate relative 78 abundance of G. vaginalis and Atopobium vaginae, 2) CST IV-B also has a moderate relative abundance of G. vaginalis and Atopobium vaginae, while 3) CST IV-C has low relative abundance 79 80 of Lactobacillus spp., as well as low levels of G. vaginalis, A. vaginae, and Ca. L. vaginae with 81 high facultative and strictly anaerobic bacteria (14). While Lactobacillus dominates the 82 cervicovaginal microbiome of Caucasians, Hispanic and black women have higher diversity and 83 reduced Lactobacillus populations (13). A previous study demonstrated that Hispanics living in 84 PR have a different microbial profile than Caucasians, and that patients with high-risk HPV and 85 CIN3 cervical lesions had dominant Atopobium vaginae and Gardnerella vaginalis (11,15). 86 However, these results could have been improved, as they identified microbiota using cervical 87 swabs, failing to address the host response. Recent studies have highlighted the benefit of

collecting cervical lavages to understand the extent of the dynamic host-microbe symbioses via
proteomic, metabolomic, or cytokine profiling analyses (16–19).

We hypothesized that there would be changes in the cervical microenvironment with cervical disease and HPV risk and that markers of inflammation would be associated with a decrease in *Lactobacillus* and overall dysbiosis. To test this hypothesis, we investigated the relationship between the cervicovaginal microbiome with cervical neoplasia and HPV infections and characterized the host immune profiles through profiling cytokine expression analyses from cervical lavages.

96 This study provides insight into specific bacterial taxonomic changes promoting a pro-97 inflammatory state associated with cervical dysplasia and represents the first effort to combine 98 microbiome and cytokine profiling in Hispanics living in Puerto Rico.

99

#### 100 Materials and Methods

#### 101 Participant Recruitment and Sample Collection

Women coming for routine medical care to the University of Puerto Rico and San Juan City clinics (San Juan Metropolitan area), were recruited as part of IRB protocol 1050114 with IBC protocol 94620. Only women who did not meet the exclusion criteria were recruited and evaluated. Exclusion criteria included: 1) Active urinary infections, 2) history of common urinary incontinence, 3) sexually transmitted diseases (STDs), 4) antibiotics taken in the prior month, 5) candidiasis, and 6) treatment for or suspicion of prior toxic shock syndrome. All subjects were informed of the study's sampling procedure, risks, and benefits with written informed consent and

a verbal explanation of the document. A detailed questionnaire from which some of the metadata
variables were collected was administered. All procedures were done according to the Declaration
of Helsinki. The date range in which human subjects' data/samples were collected was between
November 2017 and February 2020. The study and its procedures were conducted from March
2020 and October 2022.

114 A total of 91 women, 21-60 years old and able to provide informed consent, were enrolled in our 115 study. Cervical samples were collected through speculum access during the gynecological 116 examination by using cotton tip collection swabs. Sterile Catch-All Specimen Collection Swabs (Epicentre Biotechnologies, Madison WI, United States) were placed in the cervix, rotated along 117 118 the lumen with a circular motion, and then placed in sterile 2 milliliters (mL) microtubes with cap. 119 We collected approximately 10mL of cervical lavages (CVL) by injecting pure certified nuclease-120 free water (Growcells, Irvine, CA) into the vaginal canal. Collected lavages were stored in a clean 121 15mL collection tube and pH was measured with hydrion wide range pH paper strips (Merck, 122 Germany). All samples were stored at -80°C and processed for nucleic acid extraction and 123 cytokine profiling at our UPR School of Medicine laboratory to reduce processing variation.

124

125 Cytokine Detection and Measurement with Bio-Plex Immunoassay 126 System

A total of 91 cervical lavages were tested in duplicate with a multiplex solid-based immunoassay
(Bio-Plex Pro Human Cytokine 10-plex Assay, Bio-Rad) using the same volume of CVL across
samples (80 uL) for the Luminex MAGPIX® system. Cytokines/chemokines analyzed were IL1β, IL-4, IL-6, IL-8, IL-10, TNF-α, IFNγ, IP10, MIP1, and MCP1. Also, 91 samples were tested

in duplicate using Bio-Plex Pro TGF-β 3-plex immunoassay (BioRad, Hercules, CA, USA). We
performed all analyses following the manufacturer's recommendations.

133

#### 134 Cytokine/Chemokine Profile Analyses

135 Data were analyzed with the Bio-Plex Manager 6.1 software (BIO-RAD, Hercules, CA) using a 136 5-parameter logistic curve that was verified for normality before statistical testing (20). 137 Inflammation scores were assigned to each cytokine/chemokine for each sample using Fluorescent 138 Intensity (FI) results. Scores were calculated by distributing samples across statistical quartiles or 139 tertiles. If a sample was within the first quartile, a score of 1 was assigned, that is for all other three 140 quartiles (score 1 < 0.25 < score 2 < 0.50 < score 3 < 0.75 < score 4 < 1). TGF- $\beta$  scores were 141 calculated using tertiles with scoring categories including: score 1 < 0.33, score 2 from 0.33 to 0.66 and score 3 < 1. Cytokines were grouped according to their function on host physiology, 142 143 including: pro-inflammatory (IL-1β, TNF-α, IFNγ, IL-6), anti-inflammatory (IL-4, IL-10, TGFβ1) 144 and traffic-associated cytokines(IL-8, MIP1a, MCP1, IP10) (21,22). With the scoring in either 145 tertiles or quartiles, we also created a categorical variable, to which scores of 2 or 1 corresponded 146 to low levels of cytokines and > 2 high levels. These ranked score assignments using the 147 distribution of cytokines were directly related to the concentration (fluorescence intensity) of 148 cytokines/chemokines in a sample. Therefore, we used them to combine microbial community 149 analysis (16S rDNA profiles) with inflammation scores as a metadata variable (see methods section "Statistical Analyses of the Microbiota Profiles" for more details). This combination 150 151 allowed us to detect specific taxa associated with altered cytokine profiles. For comparisons 152 between multiple groups, we used ANOVA, and for comparisons between two groups, we used 153 the student's *t*-test. All statistical analyses were done using GraphPad Prism 6.0 (San Diego, CA).

154

#### 155 DNA Extraction and 16S rDNA Sequencing

156 Genomic DNA extractions from swabs were performed with the Qiagen Power Soil Kit (QIAGEN

157 LLC, Germantown Road, Maryland, USA) following an optimized protocol for these types of

158 samples as described in a previous study (11). DNA was quantified with a Qubit® dsDNA HS
159 (High Sensitivity) Assay (Waltham, Massachusetts, US) (ranging from 5-100ng/µL). An average

160 of 10-30ng/ $\mu$ L genomic DNA was shipped to an outsourced sequencing facility.

161 DNA from cervical samples was normalized to 4nM during 16S library prep. The V4 162 hypervariable region of the 16S ribosomal RNA marker gene (~291bp) was amplified using 163 universal bacterial primers: 515F (5'GTGCCAGCMGCCGCGGTAA3') 806R and 164 (5'GGACTACHVGGGTWTCTAAT3') in the Earth Microbiome Project as (http://www.earthmicrobiome.org/emp-standard-protocols/16s/) (23). The 16S-rRNA reads and 165 corresponding sample metadata was deposited in OIITA study ID 12871 (24), and the raw 166 167 sequences are available in the European Nucleotide Archive ENA Project under accession number 168 EBI: ERP136546.

169

#### 170 HPV Genotyping process

We used a kit based on a highly sensitive short-polymerase chain reaction-fragment assay (Labo Biomedical Products, Rijswijk, The Netherlands, licensed Innogenetics technology). It uses SPF10 primers to amplify a 65-bp fragment of the L1 open reading frame of HPV genotypes, followed by a Reverse-Hybridization step to determine which HPV type is present by comparing to kitprovided controls. This assay allows for the identification of the following common mucosal HPV genotypes: 14 High-risk types including (HPV 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66

and 68/73) and 11 Low-risk types (6, 11, 34, 40,42, 43, 44, 53, 54,70, 74). Previous studies explain
the method in detail (Vargas-Robles et al. 2018)Godoy-Vitorino et al. 2018 ).

179

#### 180 Quality Control and Sequence Processing

Raw read pre-processing of demultiplexed files was done with a Phred offset of 33 and default 181 182 parameters using split libraries FASTQ (QIIMEq2 1.9.1) in QIITA (24). Sequences were trimmed 183 to 250 bp, followed by the deblurring workflow (deblur 1.1.0) (24,25). For taxonomy assignment 184 we used a modified Greengenes reference database (Greengenes 13.8) (26.27) with a minimum 185 similarity threshold of 97%. The species table was downloaded for downstream analyses using a 186 locally run version of OIIME (28). Singletons, amplicon sequence variants (ASVs) with less than 187 three reads, and sequences matching chloroplasts, mitochondria, and taxonomically unassigned 188 sequences were removed from downstream analyses. All samples were rarefied to 7400 reads per 189 sample.

190

# 191 Vaginal Community State Type Nearest Centroid Classifier192 (VALENCIA)

The taxonomy of cervical microbial communities was sorted into categories termed community state types (CSTs). This categorization collapses a taxonomic profile into a single categorical variable, allowing data exploration and statistical modeling (14). In addition, categorization allows unbiased analysis of small and sizable vaginal microbiota datasets, comparisons between datasets, and meta-analyses that combine multiple datasets. We used the data package at github.com/ravel-

198 lab/VALENCIA to analyze the following standard parameters and categorize our cervicovaginal
199 communities into different CST and sub-CST categories (14).

200

#### 201 Analyses of Microbial Community Structure and Diversity

For community-level analyses, we computed the pairwise Bray-Curtis distances (Beta diversity) which quantify the compositional dissimilarity between samples (29). We visualized bacterial community composition and structure differences using non-metric multidimensional scaling (NMDS). Alpha diversity measure of Chao1 (richness), and Shannon index (30) (diversity) were computed and plotted using R with packages: "phyloseq", "vegan" and "ggplot2" (31–33). Bar Plots showing genus and species-level taxa were computed using a locally run version of QIIME2 (28).

The metadata variables included in our study were: 1) cervical disease, defined as the cytological phenotype of negative for intraepithelial lesion or malignancy (NILM), low-grade squamous intraepithelial lesion (LGSIL) and high-grade squamous intraepithelial lesion (HGSIL); 2) HPV risk, defined as HPV negative, HPV positive with co-infection (low and high-risk HPV simultaneously), and HPV positive high-risk (exclusively high-risk types); 3) cytokine ranks (estimated through quartile and tertile distribution of the fluorescence scores as detected by Luminex MAGPIX® system); and 4) community state types (CSTs).

216

#### 217 Statistical Analyses of the Microbiota Profiles

For beta diversity analyses, we tested if distances between sample groups were statisticallysignificant using ANOSIM, a non-parametric statistical test (34). Using a Bray-Curtis distance

220 table, we used this test to compare ranked beta diversity distances between the different variables. 221 These tests were done using the script "gime diversity beta-group-significance" for each specific 222 test in QIIME2 (28) with the distance matrix as the input file and 999 permutations (34). Statistical 223 analyses for alpha diversity were done using the script "qiime diversity alpha-group-significance" 224 in QIIME2 (28), which uses a non-parametric t-test with Monte Carlo permutations. Additionally, 225 to ascertain if there are statistically significant differences between the ASV abundance in the 226 different sample groups, we used linear discriminant analysis (LDA) effect size (LEfSe) (35) 227 through R, using MicrobiomeAnalyst (36). Significant ASVs were determined considering a p-228 value of < 0.05 and LDA scores of 1.5 for all cytokine groups. Cytokine fluorescence values (as 229 logarithms) were associated to differentially abundant levels of L. crispatus, L. iners, Sneathia, 230 Gardnerella, Atopobium and Prevotella using a linear mixed model (LMM) in R (ggplot and reshape2 libraries), correcting for age and body mass index (BMI). Differential abundance analysis 231 232 was performed using amplicon sequence variants corresponding to L. crispatus, L. iners, Sneathia, 233 Atopobium, Gardnerella and Prevotella. They were evaluated for their differential presence across 234 the cytokine groups. Initially, a summary of each one of the ASVs of interest was used to perform 235 groupings due to abundance. The groupings were separated as follows ASV 0-50 counts = very 236 low abundance; ASV count 51-500 = low abundance; and >500 = high abundance.

237

#### 238 Results

Population description and Community State Types (CSTs) prevalence
A total of 91 women were included in the study. The mean age was 39 years old. Women had an
average pH value of 5.49. The distribution of the groups of samples according to cervical neoplasia

242 severity included Negative for Intraepithelial Lesion or Malignancy (NILM) (N=56) Low-Grade 243 Squamous Intraepithelial Lesion (LGSIL) (N=18), and High Grade Squamous Intraepithelial 244 Lesion (HGSIL) (N=17), with differential HPV status and cytokine ranks (Table 1, S1 Table). 245 HPV infections had a prevalence of 67.0% (including infections with any HPV type) with a higher 246 prevalence of HPV+ among women with LGSIL (94.4%) and HSIL lesions (88.2%) (Table 1). As 247 expected, HR-HPV prevalence was higher in HGSIL (82.4%) compared to in LGSIL (50.0%) and 248 negative cervical lesions (39.3%) (p=0.015). Participants with HPV co-infection were primarily 249 observed in participants with low-grade lesions (44.4%) (p=0.040), and less abundant in the group 250 with high-grade lesions (5.9%). There were no significant differences in the distribution of the 251 BMI groups across cervical disease, with equal proportions of normal weight, overweight and 252 obese women (Table1). Across all women, cervical lesion prevalence was 38.5% (including 253 LGSIL and HGSIL), Individually, LGSIL and HGSIL comprised 19.8% and 18.7% of the samples, 254 respectively. CST1 mainly was present in 16% of the NILM cases and 22% LGSIL while not being 255 present in HGSIL. In contrast, CST IV-B was only identified on participants with high-grade 256 lesions (HGSIL) (p=0.025) (Table 1). Prevalence analysis of CSTs per levels (high and low) of 257 cytokine groups (pro-inflammatory, traffic-associated, and anti-inflammatory) revealed that CST 258 IV-C is the more prevalent in all cytokines (S1 Fig., S2 Table).

259	Table 1	. Characterist	tics of the	population.
-----	---------	----------------	-------------	-------------

	NILM	LGSIL	HGSIL	TRUE	P-value *
	(N=56)	(N=18)	(N=17)	(N=91)	
Age					
Mean (SD)	40.4 (12.0)	39.6 (9.55)	33.9 (9.47)	39.1 (11.3)	0.213

Med	lian [Min, Max]	38.5 [21.0, 60.0]	38.5 [25.0, 56.0]	33.0 [22.0, 56.0]	37.0 [21.0, 60.0]	
BM	I_Analysis					
Nori	mal	20 (35.7%)	5 (27.8%)	7 (41.2%)	32 (35.2%)	NS
Obe	se	18 (32.1%)	8 (44.4%)	5 (29.4%)	31 (34.1%)	
Ove	rweight	18 (32.1%)	4 (22.2%)	5 (29.4%)	27 (29.7%)	
Not	recorded	0 (0%)	1 (5.6%)	0 (0%)	1 (1.1%)	
pН						
Mea	in (SD)	5.50 (0.500)	5.36 (0.413)	5.60 (0.573)	5.49 (0.500)	0.486
Med	lian [Min, Max]	5.50 [5.00, 7.00]	5.25 [5.00, 6.00]	5.50 [5.00, 6.50]	5.50 [5.00, 7.00]	
HPV	V_Status					
HPV	/-	27 (48.2%)	1 (5.6%)	2 (11.8%)	30 (33.0%)	
HPV	/+	29 (51.8%)	17 (94.4%)	15 (88.2%)	61 (67.0%)	2.48EE-4
HPV	V_Risk					
HPV	/-	27 (48.2%)	1 (5.6%)	2 (11.8%)	30 (33.0%)	0.003
Co-i	infection	7 (12.5%)	8 (44.4%)	1 (5.9%)	16 (17.6%)	0.040
Higł	h_Risk	22 (39.3%)	9 (50.0%)	14 (82.4%)	45 (49.5%)	0.016
CST	ſ					
Ι		9 (16.1%)	4 (22.2%)	0 (0%)	13 (14.3%)	
IV-A	A	12 (21.4%)	5 (27.8%)	5 (29.4%)	22 (24.2%)	
IV-C	C	35 (62.5%)	9 (50.0%)	8 (47.1%)	52 (57.1%)	
IV-E	3	0 (0%)	0 (0%)	4 (23.5%)	4 (4.4%)	0.025

\*Kruskal-Wallis test for continuous and Fisher's test for categorical variables

#### 261

Cytokine changes according to high-grade lesions and community statetypes (CSTs)

264 There were significant differences in fluorescence between pro-inflammatory cytokines IL-1 $\beta$  and 265 IFNy among women with high grade disease, compared to healthy participants. There was significantly higher fluorescence values between HGSIL and (NILM / HPV- p=0.008) or with 266 participants with low-grade disease (p=0.015) (Fig. 1 A). Although there were no significant 267 268 differences among groups when evaluating traffic-associated cytokines (Fig. 1B) or anti-269 inflammatory cytokines (Fig. 1C), there was a tendency for higher fluorescence levels in 270 participants with any cervical disease (LGSIL and HGSIL). Although an analysis evaluating the 271 cytokines according to HPV risk was done, no significant differences were identified (S2 Fig.).

Evaluation of cytokines according to CSTs revealed significant differences in IL-1 $\beta$ , IL-6, MIP1a and IP10 concentrations. CST IV-B was found to be associated with a significantly higher concentration of IL-1 $\beta$  (p=1.0EE-4), IL-6 (p=0.050) and MIP1a (p=0.008) when compared to *Lactobacillus*-dominated CST I. (Fig. 2). In contrast, IP10 was significantly higher in CST I compared to CST IV-A (p=0.031) (Fig. 2).

Fig. 1. Cytokine Profiles grouped as pro inflammatory (A) (IL-1β, TNFα, IFNy, IL-6), antiinflammatory (B) (IL-4, IL-10, TGFβ1) and traffic-associated cytokines(C) (IL-8, MIP1a, MCP1,
IP10) cytokines evaluated through LUMINEX and plotted according to cervical disease.
Fluorescence Intensity values were used to compute multiple comparison analysis using ordinary
one-way ANOVA with Tukey's multiple comparisons test. Results were depicted in boxplots for
cervical disease. Significant differences are highlighted by brackets and corresponding p-values.

283

Fig. 2. Cytokine Profiles of IL-1β, IL-6, MIP1a and IP10 cytokines evaluated through
 LUMINEX, plotted according to CST classification. Fluorescence Intensity values were used

to compute multiple comparison analyses using ordinary one-way ANOVA with Tukey's multiple
 comparisons tests. Results are depicted in boxplots for cervical disease, and brackets and
 corresponding p-values highlight significant differences.

289

HPV infection and cervical disease are associated with altered bacterial

291 community composition

A total of 2,067,074 good-quality 16S rRNA sequence reads and 8,167 OTUs were analyzed, with 292 293 a rarefaction level of 7,400 reads per sample. Our samples mainly included reproductive-age 294 women (n = 73) and women in menopause (n = 18). To evaluate whether changes in cervicovaginal 295 microbiota are associated according to the women's physiological state, we analyzed beta and 296 alpha diversity between these categories. We found no significant differences neither in beta 297 (Bray-Curtis) (S3 Fig. A) nor in alpha diversity (Shannon) (S3 Fig. B). The microbiota 298 composition did not reveal any unique taxa associated with any of the evaluated groups (S3 Fig. 299 C). Additionally, we evaluated the cytokine profiles associated to menopause state (S3 Fig. D, E 300 and F). We found no significant differences among menopause and non-menopause women 301 according to the cytokine profiles. All the associations of cytokines with specific taxa were 302 corrected for age.

303

Fig. 3. Diversity analyses according to cervical disease and HPV risk categories. Bray-Curtis
analysis represented by Non-metric multidimensional scaling (NMDS) using cervical disease and
HPV risk as metadata categories (A, D). Alpha diversity (Shannon) was calculated and depicted

in Figs B and E. Bar Plots depicting relative abundance of bacteria at the species level for cervical
 disease (C) and HPV risk (F). Red asterisks mean significant differences among groups (p<0.05).</li>
 309

310 We evaluated the differences in the microbiota according to cervical disease and HPV risk. Beta 311 diversity analyses considering cervical disease, revealed that bacterial community structure was 312 significantly different according to cervical disease severity (LGSIL p=0.026) (HGSIL p=0.003) 313 when compared to healthy controls (NILM/HPV-) (Fig. 3A). As for HPV risk, community 314 structure was found to be significantly altered due to HR-HPV infection (p=0.042) and HPV co-315 infections (p=0.004) compared to HPV negative samples (Fig. 3D, S3 Table). Alpha diversity 316 (Shannon) increased concomitantly to the severity of the epithelial lesions, including significant 317 differences between NILM and HGSIL (p=0.003), regardless of HPV infection (Fig. 3B, S4 Table). In contrast, alpha diversity increased in participants with HPV co-infections as compared 318 319 to HPV negatives (p=0.032) (Fig. 3E, S4 Table).

320 The microbiota composition between NILM and LGSIL participants was not different and was 321 dominated by L. crispatus and L. inners. Participants with HGSIL had a change in Lactobacillus 322 distribution, being dominated by L. inners and other taxa associated with dysbiosis, such as 323 Lachnospiraceae sp., P. bivia, A. vaginae and G. vaginalis (Fig. 3C). Bacterial composition 324 changed dramatically according to HPV Risk, favoring a predominance of L. crispatus in HPV 325 negative women, and L. iners in high-risk participants (Fig. 3F). Participants with HPV co-326 infections had a highly diverse taxonomic profile with dysbiosis associated taxa including, 327 Prevotella sp., Megasphaera sp., Sneathia, Aerococcus christinsenii and Streptococcus anginosus 328 (Fig. 3F).

As identified by linear discriminant analysis (LDA) effect size (LEfSe), putative microbial biomarkers detected *Parabacteroides* and *Akkermansia* in participants with HGSIL. As for HPV risk, we found that *Sneathia* was more abundant in HPV-negative participants with cervical disease. In addition, for HPV co-infections, we identified *Megasphaera*, *Parabacteroides*, *Akkermansia* and *Bacteroides* as significantly differentiated taxa (Fig. 4).

334

Fig. 4. Linear discriminant analysis (LDA) effect size (LEfSe) for cervical disease and HPV
risk at the Genus level. Cutoff was 1.5 LDA score and a p value of 0.05. Log-level changes in
LDA score are displayed on the x axis.

338

#### 339 Association of bacterial taxa with cytokine levels

340 In a balanced vaginal tract, Lactobacillus species impede the colonization of other bacteria that would otherwise cause infections. L. Crispatus produce lactic acid, bacteriocins and H<sub>2</sub>O<sub>2</sub> acting 341 342 as a chemical barrier (Valenti et al. 2018). Very low levels of L. crispatus, a key vaginal bacterium 343 in eubiosis, were significantly associated to high concentrations of pro-inflammatory cytokines 344 IL-1 $\beta$  (p=2.16E-6) and IFN $\gamma$  (p=0.013) (Fig. 5). High levels of L. iners were significantly 345 associated with high levels of IL-6, also a pro-inflammatory cytokine (p=0.019), suggesting that 346 this species of *Lactobacillus* might stimulate IL6 production (Fig. 5). On the contrary, low levels 347 of L. iners correlate with lower expression of IFN $\gamma$  (p=0.039) (Fig. 5). Very low levels of 348 Atopobium, a mostly pathogenic bacteria were significantly associated with low levels of IL-1 $\beta$ 349 (p=0.002). As for Sneathia, another dysbiosis associated taxa, detected at low levels, had 350 correlation with higher levels of IFN $\gamma$  (p=7.00E-6), TNF $\alpha$  (p=7.00E-4) TNF $\alpha$  (p=0.010) (Fig. 5). 351 Absence, or very low levels anaerobic Gardnerella, were associated with lower fluorescence

values of IL-1 $\beta$  (p=1.00E-6) (Fig. 5). Very low abundance *of Prevotella* correlated with lower concentrations of IL-1 $\beta$  in our samples (p=3.00E-6) (Fig. 5).

354

Fig. 5. Association of key vaginal bacteria with levels of pro-inflammatory cytokines.
Cytokine logarithm fluorescence values were associated to differentially abundant levels of *L. crispatus*, *L. iners*, *Sneathia*, *Gardnerella*, *Atopobium* and *Prevotella* using a linear mixed model
(LMM), correcting for age and BMI. Differential abundance groupings were separated as follows
ASV 0-50 counts = very low abundance; ASV count 51-500 = low abundance; and >500 = high
abundance.

361

362 In beta diversity, axis 1 of the NMDS1 plot separated samples according to their cytokine levels 363 (S4 Fig. A, D, G). When compared to healthy controls (NILM/HPV-) we found changes in 364 microbial community structure significantly associated with high levels of pro-inflammatory cytokines regardless of HPV infection (NILM/HPV-, p=0.006; NILM/HPV+, p=0.001) and 365 366 cervical disease severity (LGSIL, p=0.002; HGSIL, p=0.001) (S4 Fig. A, S3 Table). High levels 367 of anti-inflammatory cytokines associated with changes in bacterial composition in similar patterns 368 as pro-inflammatory cytokines, with significant differences regardless of HPV infection 369 (NILM/HPV-, p=0.001; NILM/HPV+, p=0.001) and cervical disease severity (LGSIL, p=0.012; 370 HGSIL, p=0.001) (S4 Fig. D, S3 Table). High levels of traffic-associated cytokines significantly 371 altered bacterial composition regardless of cervical disease severity (LGSIL, p=0.012; 372 High HGSIL, p=0.001) (S4 Fig. G, S3 Table). Alpha diversity significantly increased with 373 cytokine levels for both pro-inflammatory (NILM/HPV-, p=0.035; NILM/HPV+, p=0.002) 374 (LGSIL, p=0.002; HGSIL p=0.001) and anti-inflammatory (NILM/HPV-, p=0.039; NILM/HPV+,

375 p=0.005) (LGSIL, p=0.001; HGSIL, p=3.55E-4) cytokines regardless of HPV infection and 376 cervical disease (S4 Fig. B, 4E). Traffic-associated cytokines did not have significant alpha 377 diversity differences associated with cytokine concentrations (S4 Fig. H, S4 Table). Taxonomic 378 abundance at species level showed that in the 3 cytokine groups, populations of L. crispatus 379 decreases as cytokine levels and cervical disease severity increased. Participants with high levels 380 of cytokines and high-grade cervical disease were dominated by L. iners, as L. crispatus nearly 381 disappears. Additionally, this group of participants were dominated by Prevotella sp., A. vaginae 382 and G. vaginalis. Simultaneously, Lachnospiraceae sp. was detected mainly on participants with 383 High cytokine levels and HGSIL, confirming the dysbiosis typical of Lactobacillus depleted 384 communities (S4 Fig. C, 4F and 4I). LefSe analysis (p=0.05 and 1.5 LDA score cutoffs) revealed 385 an increase in *Lactobacillus* when pro-inflammatory and anti-inflammatory cytokines were low (Fig. 6). Low levels of traffic-associated cytokines presented anaerobic bacteria like Prevotella 386 387 and Atopobium with higher abundance (Fig. 6). In contrast, with high cytokine levels in proinflammatory and anti-inflammatory cytokines, Atopobium and Prevotella populations decreased. 388 389 Pseudomonas communities also were reduced in association with pro-inflammatory and traffic-390 associated cytokines (Fig. 6).

391

Fig. 6. Linear discriminant analysis (LDA) effect size (LEfSe) for (A) pro-inflammatory (IL1β, TNFα, IFNγ, IL-6) (LDA score 1.5), (B) anti-inflammatory (IL-4, IL-10, TGFβ1) (LDA score
2.25) and (C) traffic (IL-8, MIP1a, MCP1, IP10) (1.5 LDA score) cytokines evaluated considering
low and high cytokine levels and a p-value cutoff of 0.05.

396

#### 398 Discussion

Cervical cancer (CC) is a complex disease where the cervical environment is modified, including 399 400 cytokine expression that leads to a local immunosuppression state (18). Approximately 15 high-401 risk HPV strains cause most cervical cancers; however the detection of HPV has a low positive predictive value for invasive cervical cancer, as few HPV+ women progress to High-Grade 402 403 Squamous Intraepithelial Lesions (HGSIL) (6.37). Inflammation and the microbiome could be the 404 missing link to understanding the actual cellular mechanisms leading to dysplasia and cancer. 405 Indeed, to provide an accurate diagnosis and prognosis of cervical disease progression, screening 406 tests have limited sensitivity for histopathology and cytology (38). Our sensitive HPV genotyping 407 method demonstrated that HPV prevalence in this cohort was 67.0% (encompassing infections 408 with any HPV type) and that co-infections with any HPV serotype were primarily present in low-409 grade lesions (44.4%) and exclusively high-risk types were more prevalent in HGSIL (82.3%), a 410 prevalence previously reported by our team (11) and Hispanic and Amerindian peoples (39). This 411 higher prevalence exceeds those reported for Costa Ricans (40), or women in Surinam (41), 412 Nigeria (42), Turkey (43) or Italy (44). This can be attributed to the fact that these women are 413 recruited in colposcopy clinics and are therefore not representative of the Puerto Rican population.

Modifying the host innate immune system is a well-known feature of numerous malignancies, including HPV-driven cancers (45). HPV interferes with the cytokines, Toll-like receptors (TLRs), and the overall inflammatory process, occurring in the early stages of the immune response (46,47). Together, cytokines and TLRs identify HPV and encourage immunological signalings such as cell development and differentiation (45,47). In cervical HPV infections, an impaired immune response to the virus may lead to cervical disease progression (48). Overall, we found that

420 any HPV infection elevated all cytokine levels but not all cytokines were significant. This suggests 421 that HPV infections alone cannot drive cervical dysplasia progression to cancer (49). Most HR-422 HPV-infected women do not develop CC because an effective immune response controls the 423 infection and therefore, malignant transformation is halted (50). Additionally, HPV uses several 424 strategies to evade the immune system (Miura et al., 2010), such as reducing the amount of IFN $\gamma$ , 425 altering the activation of antiviral and antitumor immune cells such as NK cells and T cells with 426 antiviral and antitumor activity (51). In addition to this, an imbalance of the mucosal microbiome, 427 such as a loss in protective *Lactobacillus* and physicochemical changes, causes alterations of the 428 vaginal mucosa and the cervical epithelium, exercising a pattern of selective pressure on the 429 microbiota (52).

430 Several studies have already established background data on how the microbiome is modified by 431 HPV infections, stating that HPV infections alone are not enough to drive significant changes that 432 translate into epithelial modifications to cancer (11,53). Nonetheless, other studies suggested 433 changes in the composition of the vaginal microbiota associated with human papillomavirus 434 infection (54-56). Our results show greater microbiota diversity and a lower abundance of 435 lactobacilli among HPV-positive women, which is congruent with previous studies (J. E. Lee et 436 al. 2013; Oh et al. 2015; Reimers et al. 2016, Godoy-Vitorino et al. 2018). It is still unclear why 437 some HR-HPV infections clear while others persist, causing dysplasia and even cervical cancer. 438 Therefore, since only persistent HR-HPV infection has been associated with immune response and 439 vaginal dysbiosis, molecular differences between transient and persistent HR-HPV infection may 440 hold information to explain this phenomenon (37).

441 Concerning cervical lesions, we found a strong microbiome association with the cervical442 phenotype (lesion severity), with a significantly higher diversity value (Shannon) in HGSIL

compared to NILM/HPV- and NILM HPV+ participants, but not substantially different from 443 444 LGSIL. Our findings coincide with most studies suggesting an association between L. iners and 445 HGSIL (60,61). Lactobacillus produces have several mechanisms that function as a defensive 446 barrier for invasive bacteria, such as, the production of significant amounts of bacteriocins that 447 contributes to colonization the use of available glycogen to produce lactic acid, lowering vaginal 448 pH, responsible of lysing bacteria other than *Lactobacillus* (62–65)(Amir et al. 2020; Cruickshank 449 1934; O'Hanlon et al. 2013; Zhou et al. 2019). The loss of this defensive strategy due to 450 *Lactobacillus* community reduction, explains the increase of *Atopobium vaginae*, *Prevotella* spp., 451 and Gardnerella spp.

452 Our study confirms cervicovaginal microbial dysbiosis in high-risk HPV and cervical disease 453 severity associated with pro-inflammatory cytokines, validating other studies in other cohorts 454 (18,66). IL-1 $\beta$  and IFN $\gamma$  were significantly more abundant in high-grade disease participants, 455 associated with a loss in *Lactobacillus* validating previous studies where high concentrations of 456 pro-inflammatory cytokines were detected in women with cervical neoplasia (67–69). The rise 457 in IL-1 $\beta$  can be attributed to cellular mechanisms such as tumorigenesis, angiogenesis (70) or 458 metastasis (71); as well as increased risk of CC in women with high grade cervical lesions (72) 459 associated with either polymorphism (73), reactive oxygen species (ROS), COX2 or NADPH 460 oxidase (74). We found higher levels of expression of IL-6 associated with high levels of L. iners. 461 IL-6 is essential for the growth, metastasis, and initiation of cancer; affecting tumor growth, 462 differentiation, and the host immune defense mechanism (75). Many immune and nonimmune 463 cells, such as T cells, monocytes, macrophages, dendritic cells, and some cancer cells -such as CC 464 cells- produce IL-6 (76,77). IL-6 induces CC growth by vascular endothelial growth factor 465 (VEGF)-dependent angiogenesis (78). In addition, higher expression of IL-6 was shown in

466 cancerous tissues than in adjacent non-cancer tissues in early-stage CC patients, confirming its 467 association to cancer development (79). The less protective Lactobacilli (*L. iners*) may be 468 stimulating the production of these mediators, this could be due in part to their heterogeneous 469 genome, that unlike the protective counterparts, do not produce as much lactic acid or hydrogen 470 peroxide (80). Although the slight increase in IL-10 among LGSIL is not significant, we 471 hypothesize that IL-10 may increase in parallel with the development of intraepithelial lesion as it 472 does in cancer, promoting the expression of HPV oncoproteins (Berti et al. 2017).

473 Taxonomic profiles of cervical microbial communities were sorted into community state types 474 (CSTs), allowing a valuable categorization for statistical modeling and comparisons between 475 datasets (13,14). The vaginal microbiota in this Hispanic women cohort of women living in Puerto 476 Rico was dominated by CST IV-C (57.1%, non-Lactobacillus profile) and CST IV-A (24.1%, G. 477 vaginalis moderate), which confirms previous work of our lab (11), and suggests similarities to 478 other US Hispanics (13) and Venezuelans (81). Even when CST IV-C dominated all three 479 categories of cervical cytology (NILM, LGSIL, HGSIL), but was more predominant in healthy 480 patients (NILM) (62.5%). CST IV-C is characterized by a low relative abundance of Lactobacillus 481 spp., G. vaginalis, and A. vaginae, while instead is characterized by the abundance of a diverse 482 array of facultative and strictly anaerobic bacteria, thus revealing that Hispanic women living in 483 PR are in constant dysbiosis with a microbiome dominated by anaerobic non-lactobacillus 484 communities. Overall, the high prevalence of CST-IV across all samples reflects a cervical 485 microbial environment with low stability and less likelihood to return to its equilibrium state after 486 a perturbation, which increases the risk of developing adverse health outcomes (82,83). In 487 Hispanics living in Puerto Rico, the typical healthy vaginal microbial profile seems to be already 488 diverse. It does not correspond to that of US Caucasians, mostly dominated by CST-I, being more

489 like that of other US Hispanics, which are more prone to vaginal dysbiosis regulation and 490 inflammatory conditions (Ravel et al. 2011). CST-IV represents a highly diverse bacterial profile 491 and has been associated with high pro-inflammatory cytokine levels, which damage the 492 endocervix's columnar epithelial barrier, exposing it to colonization to other microbial or 493 pathogenic agents (12,84).

494 Microbiome analysis revealed that high levels of all three groups of cytokines (anti-inflammatory, 495 pro-inflammatory, and traffic-associated) were related to significant bacterial community 496 composition changes and high diversity levels (Shannon). Low levels of Sneathia spp. are 497 associated with higher concentrations of IL-1 $\beta$  and TNF $\alpha$ , this taxa that is part of the normal 498 microbiota of the genitourinary tracts of men and women is now considered a possible pathogen 499 of the female reproductive tract (85), Sneathia spp. are also regarded as good biomarkers for 500 bacterial vaginosis (86), a classical dysbiosis associated with abnormalities in cervical smears (87). 501 Previous studies have described that Lactobacillus can prevent the colonization of exogenous 502 pathogens by producing lactic acid, bacteriocins and reactive oxygen species (ROS) (13.88.89). 503 Lactobacilli, promote homeostasis in the cervicovaginal environment and are associated with low 504 levels of pro-inflammatory and anti-inflammatory cytokines. In contrast, low concentrations of 505 traffic-associated-related cytokines are associated with an increase in *Prevotella* and *Atopobium*, 506 suggesting that there is little induction of immune cell tissue migration to combat these bacteria. 507 Previous studies reported that Atopobium vaginae could trigger an innate immune response 508 involving IL-6 and IL-8 using an in vitro model of bacterial vaginosis (90), and this could be 509 happening in vivo. Also, a study suggested that Prevotella may provide nutrients such as ammonia 510 and amino acids other microbial community to members such as 511 Gardnerella and Peptostreptococcus (91), assuming a metabolic hub for vaginal microbiota and

being a key player in vaginal dysbiosis (92). *Prevotella* is therefore critical for maintaining a
dysbiotic ecosystem in the cervix.

514 Cervical cancer is a complex multifactorial disease, and further research, including time-series 515 analyses of longitudinal sampling, is needed to improve our understanding of its etiology. Our 516 study evidence that high concentrations of all three cytokine groups (inflammatory, anti-517 inflammatory, and traffic-associated) were associated with cervical dysbiosis, which occurs 518 through dramatic losses of protective *Lactobacilli* and the presence of diverse anaerobic taxa. The 519 cervical microbiota in Hispanic women living in Puerto Rico is highly diverse and dominated by 520 CSTs III and IV. Further changes of the microbiota with HR-HPV and inflammation reveal that 521 the joint host-microbe interaction analyses via cytokine signaling and microbiota in precancerous 522 lesions have great translational potential.

523

#### 524 Acknowledgments

525 We would like to acknowledge Dr. Robert D. Burk, Dr. Mykhaylo Usyk for kindly providing the 526 curated extended GreenGenes database we cite in the methods section, which integrates the 527 GreenGenes database, the Human Oral Microbiome Database (HOMD) and cervicovaginal 528 microbiome 16S reference sequences retrieved from NCBI. Also, we want to thank Dr. Michael 529 T. France for his help in adapting our taxonomy for the VALENCIA classification. We thank all 530 the medical personnel from the gynecology clinics who participated in the screening program and 531 sample collection and the students who helped with metadata curation. We offer special thanks to 532 the participants for contributing to our study.

### 534 References

535	1.	Mitchell C. PAHO/WHO   Cervical cancer is the third most common cancer among women in
536		Latin America and the Caribbean, but it can be prevented [Internet]. Pan American Health
537		Organization / World Health Organization. 2019 [cited 2022 May 17]. Available from:
538		https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14947:cervical
539		-cancer-is-the-third-most-common-cancer-among-women-in-latin-america-and-the-
540		caribbean-but-it-can-be-prevented&Itemid=1926⟨=en
541	2.	Glasgow L, Lewis R, Charles S. The cancer epidemic in the Caribbean region: Further
542		opportunities to reverse the disease trend. The Lancet Regional Health - Americas. 2022
543		Sep;13:100295.
544	3.	Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular
545		biology and disease association. Rev Med Virol. 2015 Mar;25 Suppl 1:2-23.
546	4.	Lehoux M, D'Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-
547		induced carcinogenesis. Public Health Genomics. 2009;12(5-6):268-80.
548	5.	Pradhan SR, Mahata S, Ghosh D, Sahoo PK, Sarkar S, Pal R, et al. Human Papillomavirus
549		Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism
550		of Self-Clearance [Internet]. Human Papillomavirus. IntechOpen; 2020 [cited 2022 May 17].
551		Available from: https://www.intechopen.com/chapters/70423
552	6.	Beata S, Dariusz S, Marianna M, Hanna R, Zbigniew K, Luiza W, et al. The Role of Human
553		Papillomavirus in Cervical Cancer. Int J Cancer Clin Res [Internet]. 2019 Sep 28 [cited 2022]

- 554 May 17];6(5). Available from: https://www.clinmedjournals.org/articles/ijccr/international-555 journal-of-cancer-and-clinical-research-ijccr-6-125.php?jid=ijccr
- 556 7. Okunade KS. Human papillomavirus and cervical cancer. Journal of Obstetrics and
  557 Gynaecology. 2020 Jul 3;40(5):602–8.
- 8. Conesa-Zamora P, Ortiz-Reina S, Moya-Biosca J, Doménech-Peris A, Orantes-Casado FJ,
   Pérez-Guillermo M, et al. Genotype distribution of human papillomavirus (HPV) and co infections in cervical cytologic specimens from two outpatient gynecological clinics in a
   region of southeast Spain. BMC Infect Dis. 2009 Aug 10;9:124.
- 9. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal
  microbiota, human papillomavirus and cervical dysplasia: a systematic review and network
  meta-analysis. BJOG. 2020 Jan;127(2):171–80.
- 565 10. Pfeiffer JK. Host response: Microbiota prime antiviral response. Nat Microbiol. 2016 Jan
  566 27;1:15029.
- 567 11. Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez568 Sánchez F, et al. Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial
  569 Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population. Front
  570 Microbiol. 2018;9:2533.
- 12. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An association of
  cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic
  human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1021–7.

574	13. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome
575	of reproductive-age women. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680–7.

576 14. France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, et al. VALENCIA: a nearest

577 centroid classification method for vaginal microbial communities based on composition.

578 Microbiome. 2020 Dec;8(1):166.

579 15. Godoy-Vitorino F, Romaguera J, Ortiz Morales G, Vázquez-Sánchez F, Dominicci-Maura A,
580 Ortiz A. Malassezia globosa and Malassezia restricta are associated with high-risk HPV
581 infections in the anogenital tract. Journal of Lower Genital Tract Disease. 2019 Apr
582 4;22:PMID: 30889031.

- 16. Chorna N, Romaguera J, Godoy-Vitorino F. Cervicovaginal Microbiome and Urine
  Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with
  Human Papilloma Virus Infections. Metabolites. 2020 Jan 15;10(1):36.
- 17. Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering
  the complex interplay between microbiota, HPV, inflammation and cancer through
  cervicovaginal metabolic profiling. EBioMedicine. 2019 Jun;44:675–90.
- 18. Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, MartínezBarnetche J, Cortina-Ceballos B, et al. Cervical Microbiome and Cytokine Profile at Various
  Stages of Cervical Cancer: A Pilot Study. PLoS One. 2016;11(4):e0153274.

592 19. Güzel C, Govorukhina NI, Wisman GBA, Stingl C, Dekker LJM, Klip HG, et al. Proteomic
593 alterations in early stage cervical cancer. Oncotarget. 2018 Apr 6;9(26):18128–47.

594	20. Olivier J, Johnson WD, Marshall GD. The logarithmic transformation and the geometric mean
595	in reporting experimental IgE results: what are they and when and why to use them? Ann
596	Allergy Asthma Immunol. 2008 Apr;100(4):333–7.

- 597 21. Moscicki AB, Shi B, Huang H, Barnard E, Li H. Cervical-Vaginal Microbiome and Associated
- 598 Cytokine Profiles in a Prospective Study of HPV 16 Acquisition, Persistence, and Clearance.
- 599 Frontiers in Cellular and Infection Microbiology [Internet]. 2020 [cited 2022 May 16];10.

Available from: https://www.frontiersin.org/article/10.3389/fcimb.2020.569022

- 601 22. Scott ME, Shvetsov YB, Thompson PJ, Hernandez BY, Zhu X, Wilkens LR, et al. Cervical
- 602 cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort
  603 study: Mucosal cytokines and cervical HPV clearance. Int J Cancer. 2013 Sep 1;133(5):1187–
  604 96.
- 605 23. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high606 throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME
  607 J. 2012 Aug;6(8):1621–4.
- 608 24. Gonzalez A, Navas-Molina JA, Kosciolek T, McDonald D, Vázquez-Baeza Y, Ackermann G,
  609 et al. Qiita: rapid, web-enabled microbiome meta-analysis. Nat Methods. 2018
  610 Oct;15(10):796–8.

611 25. Amir A, McDonald D, Navas-Molina JA, Kopylova E, Morton JT, Zech Xu Z, et al. Deblur
612 Rapidly Resolves Single-Nucleotide Community Sequence Patterns. Gilbert JA, editor.
613 mSystems [Internet]. 2017 Apr 21 [cited 2022 Feb 24];2(2). Available from:
614 https://journals.asm.org/doi/10.1128/mSystems.00191-16

615	26. Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal
616	microbiome and natural history of HPV in a longitudinal study. Silvestri G, editor. PLoS
617	Pathog. 2020 Mar 26;16(3):e1008376.

- 618 27. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a
- 619 Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB. Appl
- 620 Environ Microbiol. 2006 Jul;72(7):5069–72.
- 621 28. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
- 622 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
- 623 Nat Biotechnol. 2019 Aug;37(8):852–7.
- 624 29. Bray JR, Curtis JT. An Ordination of the Upland Forest Communities of Southern Wisconsin.
  625 Ecological Monographs. 1957 Oct;27(4):325–49.
- 30. Shannon CE. A Mathematical Theory of Communication. Bell System Technical Journal.
  1948 Jul;27(3):379–423.
- 31. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and
  Graphics of Microbiome Census Data. PLOS ONE. 2013 Apr 22;8(4):e61217.
- 630 32. Hadley W. Ggplot2. New York, NY: Springer Science+Business Media, LLC; 2016.
- 631 33. Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, et al. vegan:
- 632 Community Ecology Package [Internet]. 2022 [cited 2022 May 16]. Available from:
- 633 https://CRAN.R-project.org/package=vegan

- 634 34. Anderson MJ. Permutation tests for univariate or multivariate analysis of variance and
  635 regression. Can J Fish Aquat Sci. 2001 Mar 1;58(3):626–39.
- 636 35. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
- biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.
- 638 36. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical,
  639 functional, and meta-analysis of microbiome data. Nat Protoc. 2020 Mar;15(3):799–821.
- 640 37. B Q, Z J, Q S, C J, Z L, X M. Cervicovaginal microbiota dysbiosis correlates with HPV
- 641 persistent infection. Microbial pathogenesis [Internet]. 2021 Mar [cited 2022 Sep 15];152.
- 642 Available from: https://pubmed.ncbi.nlm.nih.gov/33207260/
- 38. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American
  Cancer Society, American Society for Colposcopy and Cervical Pathology, and American
  Society for Clinical Pathology screening guidelines for the prevention and early detection of
  cervical cancer. CA Cancer J Clin. 2012 Jun;62(3):147–72.
- 39. Vargas-Robles D, Magris M, Morales N, de Koning MNC, Rodríguez I, Nieves T, et al. High
  Rate of Infection by Only Oncogenic Human Papillomavirus in Amerindians. mSphere. 2018
  Jun 27;3(3):e00176-18.
- 40. Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, et al. Prevalence of and
  risk factors for anal human papillomavirus infection among young healthy women in Costa
  Rica. J Infect Dis. 2012 Oct 1;206(7):1103–10.

653	41. Geraets DT, Grünberg AW, van der Helm JJ, Schim van der Loeff MF, Quint KD, Sabajo
654	LOA, et al. Cross-sectional study of genital carcinogenic HPV infections in Paramaribo,
655	Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-
656	vaccination era. Sex Transm Infect. 2014 Dec;90(8):627–33.
657	42. Adebamowo SN, Ma B, Zella D, Famooto A, Ravel J, Adebamowo C. Mycoplasma hominis
658	and Mycoplasma genitalium in the Vaginal Microbiota and Persistent High-Risk Human
659	Papillomavirus Infection. Front Public Health. 2017 Jun 26;5:140.
660	43. Barut MU, Yildirim E, Kahraman M, Bozkurt M, Imirzalioğlu N, Kubar A, et al. Human
661	Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic
662	Status in Central Anatolia, Turkey: A Pilot Study. Med Sci Monit. 2018 Jan 4;24:58-66.
663	44. Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, et al. Monitoring
664	vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in
665	the Basilicata region, Italy. BMC Infect Dis. 2018 Jan 15;18:38.
666	45. Grabowska AK, Riemer AB. The invisible enemy - how human papillomaviruses avoid
667	recognition and clearance by the host immune system. Open Virol J. 2012;6:249-56.
668	46. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a
669	double-edged sword for defense and offense. Arch Pharm Res. 2012 Aug;35(8):1297–316.
670	47. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads
671	of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014
672	Nov;1843(11):2563–82.

- 48. Barros MR, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral Modulation of
- TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers. J
  Immunol Res. 2018 May 2;2018:2912671.
- 49. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new
  concepts and clinical implications. Cancer Med. 2018 Oct;7(10):5217–36.
- 50. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident
  cervical HPV infections in young women: transition probabilities for CIN and infection
  clearance. Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287–96.
- 51. Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV)
  infection and evasion of host defense in cervical cancer. J Infect Chemother. 2012
  Dec;18(6):807–15.
- 52. Kim TK, Thomas SM, Ho M, Sharma S, Reich CI, Frank JA, et al. Heterogeneity of vaginal
  microbial communities within individuals. J Clin Microbiol. 2009 Apr;47(4):1181–9.
- 686 53. Bienkowska-Haba M, Luszczek W, Myers JE, Keiffer TR, DiGiuseppe S, Polk P, et al. A new

cell culture model to genetically dissect the complete human papillomavirus life cycle. PLOS
Pathogens. 2018 Mar 1;14(3):e1006846.

54. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E.
The vaginal microbiota and its association with human papillomavirus, Chlamydia
trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic
review and meta-analysis. Clin Microbiol Infect. 2019 Jan;25(1):35–47.

693	55. Gillet E, Meys JFA, Verstraelen H, Verhelst R, De Sutter P, Temmerman M, et al. Association
694	between Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Systematic Review and
695	Meta-Analysis. PLoS One. 2012 Oct 2;7(10):e45201.

- 56. Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of
- 697 human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet
- 698 Gynecol. 2019 Jul;221(1):9-18.e8.
- 699 57. Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, et al. Association of the vaginal microbiota
- with human papillomavirus infection in a Korean twin cohort. PLoS One. 2013;8(5):e63514.
- 58. Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, et al. The association of uterine cervical
  microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. Clin
  Microbiol Infect. 2015 Jul;21(7):674.e1-9.
- 59. Reimers LL, Mehta SD, Massad LS, Burk RD, Xie X, Ravel J, et al. The Cervicovaginal
- Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and
   HIV-Uninfected Women. J Infect Dis. 2016 Nov 1;214(9):1361–9.
- Fredricks DN, Fiedler TL, Marrazzo JM. Molecular Identification of Bacteria Associated with
  Bacterial Vaginosis. N Engl J Med. 2005 Nov 3;353(18):1899–911.
- 709 61. Cancer Facts & Figures for Hispanic/Latino People 2021-2023. :40.
- 62. Amir M, Brown JA, Rager SL, Sanidad KZ, Ananthanarayanan A, Zeng MY. Maternal
  Microbiome and Infections in Pregnancy. Microorganisms. 2020 Dec 15;8(12):E1996.

- 63. O'Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when
  lactobacilli dominate the microbiota. PLoS One. 2013;8(11):e80074.
- 64. Cruickshank R. The conversion of the glycogen of the vagina into lactic acid. The Journal of

Pathology and Bacteriology. 1934;39(1):213–9.

- 716 65. Zhou Y, Wang L, Pei F, Ji M, Zhang F, Sun Y, et al. Patients With LR-HPV Infection Have a
- 717 Distinct Vaginal Microbiota in Comparison With Healthy Controls. Front Cell Infect718 Microbiol. 2019;9:294.
- 66. Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, et al. Linking cervicovaginal
  immune signatures, HPV and microbiota composition in cervical carcinogenesis in nonHispanic and Hispanic women. Sci Rep. 2018 Dec;8(1):7593.
- 67. Campisciano G, Zanotta N, Licastro D, De Seta F, Comar M. In vivo microbiome and
  associated immune markers: New insights into the pathogenesis of vaginal dysbiosis. Sci Rep.
  2018 Feb 2;8(1):2307.
- 68. De Seta F, Campisciano G, Zanotta N, Ricci G, Comar M. The Vaginal Community State
  Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic
  Vaginitis. Front Microbiol. 2019;10:2451.
- 69. Torcia MG. Interplay among Vaginal Microbiome, Immune Response and Sexually
  Transmitted Viral Infections. Int J Mol Sci. 2019 Jan 11;20(2):E266.

730	70. Filippi I, Carraro F, Naldini A. Interleukin-1ß Affects MDAMB231 Breast Cancer Cell
731	Migration under Hypoxia: Role of HIF-1 $\alpha$ and NF $\kappa$ B Transcription Factors. Mediators
732	Inflamm. 2015;2015:789414.

- 733 71. Apte RN, Voronov E. Is interleukin-1 a good or bad "guy" in tumor immunobiology and
  734 immunotherapy? Immunol Rev. 2008 Apr;222:222–41.
- 735 72. Iwata T, Fujii T, Morii K, Saito M, Sugiyama J, Nishio H, et al. Cytokine profile in cervical
  736 mucosa of Japanese patients with cervical intraepithelial neoplasia. Int J Clin Oncol. 2015
  737 Feb;20(1):126–33.
- 738 73. Qian N, Chen X, Han S, Qiang F, Jin G, Zhou X, et al. Circulating IL-1beta levels,
  739 polymorphisms of IL-1B, and risk of cervical cancer in Chinese women. J Cancer Res Clin
  740 Oncol. 2010 May;136(5):709–16.
- 741 74. Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, et al. Downregulation of
- $15-hydroxy prostagland in dehydrogen as by interleukin-1\beta from activated macrophages leads$
- to poor prognosis in pancreatic cancer. Cancer Sci. 2018 Feb;109(2):462–70.
- 744 75. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for
  745 cancer. Cancer Treat Rev. 2012 Nov;38(7):904–10.
- 746 76. Pahne-Zeppenfeld J, Schröer N, Walch-Rückheim B, Oldak M, Gorter A, Hegde S, et al.
- 747 Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-
- expressing dendritic cells. International Journal of Cancer. 2014;134(9):2061–73.

- 749 77. Suradej B, Sookkhee S, Panyakaew J, Mungkornasawakul P, Wikan N, Smith DR, et al.
  750 Kaempferia parviflora Extract Inhibits STAT3 Activation and Interleukin-6 Production in
  751 HeLa Cervical Cancer Cells. International Journal of Molecular Sciences. 2019
  752 Jan;20(17):4226.
- 753 78. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical
  754 tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003
  755 Mar;22(10):1517–27.
- 756 79. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical
  757 cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001
  758 Jul;82(1):49–56.
- 80. Choi HS, Kim KM, Kim CH, Kim SM, Oh JS. Hydrogen Peroxide Producing Lactobacilli in
  Women with Cervical Neoplasia. Cancer Res Treat. 2006 Apr;38(2):108–11.
- 761 81. Vargas-Robles D, Morales N, Rodríguez I, Nieves T, Godoy-Vitorino F, Alcaraz LD, et al.
  762 Changes in the vaginal microbiota across a gradient of urbanization. Sci Rep. 2020
  763 Dec;10(1):12487.
- 82. Eastment MC, McClelland RS. Vaginal microbiota and susceptibility to HIV. AIDS. 2018 Mar
  27;32(6):687–98.
- 766 83. Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, et al. Human papillomavirus infection and
  767 cervical intraepithelial neoplasia progression are associated with increased vaginal
  768 microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020 Aug 26;20(1):629.

769	84. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al.
770	Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female
771	genital tract. Immunity. 2015 May 19;42(5):965–76.

- 772 85. Harwich MD, Serrano MG, Fettweis JM, Alves JMP, Reimers MA, Vaginal Microbiome
- 773 Consortium (additional members), et al. Genomic sequence analysis and characterization of

Sneathia amnii sp. nov. BMC Genomics. 2012;13 Suppl 8:S4.

- 86. Shipitsyna E, Roos A, Datcu R, Hallén A, Fredlund H, Jensen JS, et al. Composition of the
- vaginal microbiota in women of reproductive age--sensitive and specific molecular diagnosis

of bacterial vaginosis is possible? PLoS One. 2013;8(4):e60670.

778 87. Caixeta RCA, Ribeiro AA, Segatti KD, Saddi VA, Fig.ueiredo Alves RR, dos Santos Carneiro

MA, et al. Association between the human papillomavirus, bacterial vaginosis and cervicitis

and the detection of abnormalities in cervical smears from teenage girls and young women.

- 781 Diagn Cytopathol. 2015 Oct;43(10):780–5.
- 88. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate
  ratio is consistent with bacteria being the primary source. Hum Reprod. 2001 Sep;16(9):1809–
  13.
- 785 89. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women's health, and reproductive
  786 outcomes. Fertil Steril. 2018 Aug;110(3):327–36.
- 90. Libby EK, Pascal KE, Mordechai E, Adelson ME, Trama JP. Atopobium vaginae triggers an
  innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. 2008
  Apr;10(4):439–46.

790	91. Vyshenska D, Lam KC, Shulzhenko N, Morgun A. Interplay between viruses and bacterial
791	microbiota in cancer development. Semin Immunol. 2017 Aug;32:14-24.
792	92. Si J, You HJ, Yu J, Sung J, Ko G. Prevotella as a Hub for Vaginal Microbiota under the
793	Influence of Host Genetics and Their Association with Obesity. Cell Host Microbe. 2017 Jan
794	11;21(1):97–105.

795

Supporting information 796

797 S1 Fig. CST prevalence distribution among cytokine levels and groups. CSTs according to 798 category groups were used to compute Fisher's test using pairwise analysis to compare between 799 groups. Results were depicted in boxplots for cervical disease. Significant differences are 800 highlighted by brackets and corresponding p-values.

801

802 **S2 Fig.** Cytokine Profiles of (A) pro inflammatory (IL-1B, TNFa, IFNy, IL-6), (B) anti-803 inflammatory (IL-4, IL-10, TGFB1) and (C) traffic (IL-8, MIP1a, MCP1, IP10) cytokines 804 evaluated through LUMINEX, plotted according to HPV risk. Fluorescence Intensity values were used to compute multiple comparison analysis using ordinary one-way ANOVA with Tukey's 805 806 multiple comparisons test. Results were depicted in boxplots for cervical disease. Significant 807 differences are highlighted by brackets and corresponding p-values.

808

809 S3 Fig. Diversity and cytokine profile analyses comparing samples, according to menopause status. Beta and alpha diversity analyses are represented by non-metric multidimensional scaling 810

(NMDS) (A) and Shannon index boxplots (B). Relative abundance of bacteria at the species level
is shown in a relative abundance bar plot (C). Cytokine Profiles of pro inflammatory (D), antiinflammatory (E) and traffic (F) cytokines, plotted according to HPV risk. Fluorescence Intensity
values were used to compute multiple comparison analysis using ordinary one-way ANOVA with
Tukey's multiple comparisons test. Significant differences are highlighted by brackets and
corresponding p-values.

817

818	S4 Fig. Diversity analyses comparing samples, according to inflammatory (IL-1β, TNFa,
819	IFNg, IL-6), anti-inflammatory (IL-4, IL-10, TGFβ1), and trafficking (IL-8, MIP1a, MCP1,
820	IP10) cytokines. Bray-Curtis analysis represented by Non-metric multidimensional scaling
821	(NMDS) using pro inflammatory (A), anti-inflammatory (D) and trafficking cytokines (G) as
822	metadata categories. Alpha diversity (Shannon) was calculated and depicted in Figures B, E and
823	H. Bar Plots showing relative abundance of bacteria at the species level for cytokine groups (C, F
824	I).

825

826 S1 Table. Study population characteristics (n=91) described by cervical disease status,
827 including HPV risk, community state types, and cytokine ranks.


828

829 S2 Table. Pairwise comparisons using Pairwise comparison of proportions (Fisher) of the
830 cytokine levels. P values were adjusted using Bonferroni corrections.


- 832 S3 Table. Non-parametric analyses using ranked beta diversity distances between different
- 833 group depths found in the mapping file, based on the Bray-Curtis table.


- 835 S4 Table. Non-parametric t-test comparing observed richness between the different
- 836 metadata categories

## L. crispatus




### Gardnerella






L. iners




Sneathia

Fluorescent Intensity (FI)

Prevotella





TNF-α

IP10

